JP2017502997A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502997A5 JP2017502997A5 JP2016546998A JP2016546998A JP2017502997A5 JP 2017502997 A5 JP2017502997 A5 JP 2017502997A5 JP 2016546998 A JP2016546998 A JP 2016546998A JP 2016546998 A JP2016546998 A JP 2016546998A JP 2017502997 A5 JP2017502997 A5 JP 2017502997A5
- Authority
- JP
- Japan
- Prior art keywords
- peg
- vesicle
- vesicles
- group
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 19
- -1 cationic lipid Chemical class 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 239000012528 membrane Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000004055 small Interfering RNA Substances 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- NYZTVPYNKWYMIW-WRBBJXAJSA-N 4-[[2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl-dimethylazaniumyl]methyl]benzoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)CC1=CC=C(C=C1)C([O-])=O)OC(=O)CCCCCCC\C=C/CCCCCCCC NYZTVPYNKWYMIW-WRBBJXAJSA-N 0.000 claims 3
- 239000000232 Lipid Bilayer Substances 0.000 claims 3
- 108091027967 Small hairpin RNA Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 244000052769 pathogen Species 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 108020005004 Guide RNA Proteins 0.000 claims 2
- 108010034143 Inflammasomes Proteins 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- BVKFQEAERCHBTG-UHFFFAOYSA-N 17,18,19-trihydroxypentatriacontane-16,20-dione Chemical compound CCCCCCCCCCCCCCCC(=O)C(O)C(O)C(O)C(=O)CCCCCCCCCCCCCCC BVKFQEAERCHBTG-UHFFFAOYSA-N 0.000 claims 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- LRFJOIPOPUJUMI-KWXKLSQISA-N 2-[2,2-bis[(9z,12z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-n,n-dimethylethanamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC1(CCCCCCCC\C=C/C\C=C/CCCCC)OCC(CCN(C)C)O1 LRFJOIPOPUJUMI-KWXKLSQISA-N 0.000 claims 1
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 claims 1
- VGHMMKAOWFINON-UHFFFAOYSA-N 3-[2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl-methylamino]propanoic acid Chemical compound C(CCCCCCCC=C/CCCCCCCC)(=O)OC(CN(CCC(=O)O)C)COC(CCCCCCCC=C/CCCCCCCC)=O VGHMMKAOWFINON-UHFFFAOYSA-N 0.000 claims 1
- 241000224489 Amoeba Species 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- JEFHZBOWUMVAQD-UHFFFAOYSA-N C(CCCCCCCC=C/CCCCCCCC)(=O)OC(CN(C)CC1=CC=C(C(=O)O)C=C1)COC(CCCCCCCC=C/CCCCCCCC)=O Chemical compound C(CCCCCCCC=C/CCCCCCCC)(=O)OC(CN(C)CC1=CC=C(C(=O)O)C=C1)COC(CCCCCCCC=C/CCCCCCCC)=O JEFHZBOWUMVAQD-UHFFFAOYSA-N 0.000 claims 1
- COZACIHWINTJON-YEUCEMRASA-N CCCCCCCC/C=C\CCCCCCCC(OCC(C[N+](C)(C)CC(C)C([O-])=O)OC(CCCCCCC/C=C\CCCCCCCC)=O)=O Chemical compound CCCCCCCC/C=C\CCCCCCCC(OCC(C[N+](C)(C)CC(C)C([O-])=O)OC(CCCCCCC/C=C\CCCCCCCC)=O)=O COZACIHWINTJON-YEUCEMRASA-N 0.000 claims 1
- 108091079001 CRISPR RNA Proteins 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 claims 1
- NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 claims 1
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- 125000005233 alkylalcohol group Chemical group 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 210000001772 blood platelet Anatomy 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 210000002583 cell-derived microparticle Anatomy 0.000 claims 1
- 150000001783 ceramides Chemical class 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 150000001982 diacylglycerols Chemical class 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 125000005265 dialkylamine group Chemical group 0.000 claims 1
- 150000001985 dialkylglycerols Chemical class 0.000 claims 1
- UAKOZKUVZRMOFN-JDVCJPALSA-M dimethyl-bis[(z)-octadec-9-enyl]azanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC[N+](C)(C)CCCCCCCC\C=C/CCCCCCCC UAKOZKUVZRMOFN-JDVCJPALSA-M 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000001808 exosome Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 244000053095 fungal pathogen Species 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 210000000224 granular leucocyte Anatomy 0.000 claims 1
- NRLNQCOGCKAESA-UHFFFAOYSA-N heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate Chemical compound CCCCCC=CCC=CCCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCCC=CCC=CCCCCC NRLNQCOGCKAESA-UHFFFAOYSA-N 0.000 claims 1
- 229920001519 homopolymer Polymers 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003622 mature neutrocyte Anatomy 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000002082 metal nanoparticle Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 claims 1
- XVUQPECVOGMPRU-ZPPAUJSGSA-N n,n-dimethyl-1,2-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOC(C)C(N(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC XVUQPECVOGMPRU-ZPPAUJSGSA-N 0.000 claims 1
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 claims 1
- YNTOKMNHRPSGFU-UHFFFAOYSA-N n-Propyl carbamate Chemical compound CCCOC(N)=O YNTOKMNHRPSGFU-UHFFFAOYSA-N 0.000 claims 1
- 229940031182 nanoparticles iron oxide Drugs 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 108010091748 peptide A Proteins 0.000 claims 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 1
- 239000002096 quantum dot Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461929559P | 2014-01-21 | 2014-01-21 | |
| US61/929,559 | 2014-01-21 | ||
| PCT/IB2015/050436 WO2015110957A2 (en) | 2014-01-21 | 2015-01-20 | Hybridosomes, compositions comprising the same, processes for their production and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019113819A Division JP7046872B2 (ja) | 2014-01-21 | 2019-06-19 | ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502997A JP2017502997A (ja) | 2017-01-26 |
| JP2017502997A5 true JP2017502997A5 (enExample) | 2017-12-21 |
| JP6598786B2 JP6598786B2 (ja) | 2019-10-30 |
Family
ID=52434912
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016546998A Active JP6598786B2 (ja) | 2014-01-21 | 2015-01-20 | ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用 |
| JP2019113819A Active JP7046872B2 (ja) | 2014-01-21 | 2019-06-19 | ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用 |
| JP2022045805A Pending JP2022101548A (ja) | 2014-01-21 | 2022-03-22 | ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019113819A Active JP7046872B2 (ja) | 2014-01-21 | 2019-06-19 | ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用 |
| JP2022045805A Pending JP2022101548A (ja) | 2014-01-21 | 2022-03-22 | ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10561610B2 (enExample) |
| EP (2) | EP3096741B1 (enExample) |
| JP (3) | JP6598786B2 (enExample) |
| KR (3) | KR102541164B1 (enExample) |
| CN (2) | CN105934240B (enExample) |
| AU (3) | AU2015208837B2 (enExample) |
| CA (1) | CA2936514C (enExample) |
| DK (1) | DK3096741T3 (enExample) |
| EA (1) | EA037503B1 (enExample) |
| ES (1) | ES2821758T3 (enExample) |
| MX (2) | MX384911B (enExample) |
| WO (1) | WO2015110957A2 (enExample) |
| ZA (1) | ZA201604831B (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140308212A1 (en) | 2011-11-07 | 2014-10-16 | University Of Louisville Research Foundation, Inc. | Edible plant-derived microvesicle compositions for diagnosis and treatment of disease |
| WO2014210448A1 (en) | 2013-06-27 | 2014-12-31 | The Board Of Regents Of The University Of Texas System | Compositions and methods relating to myomaker-induced muscle cell fusion |
| EP3096741B1 (en) | 2014-01-21 | 2020-09-02 | Anjarium Biosciences AG | Process for the production of hybridosomes |
| WO2015157652A1 (en) | 2014-04-11 | 2015-10-15 | University Of Louisville Research Foundation, Inc. | Coated edible plant-derived microvesicle compositions and methods for using the same |
| CA3012985A1 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| WO2017136430A1 (en) | 2016-02-01 | 2017-08-10 | The Board Of Trustees Of The Leland Stanford Junior University | Exosome-total-isoloation-chip (exotic) device for isolation of exosome-based biomarkers |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| CN107362370B (zh) * | 2016-05-13 | 2022-07-26 | 国家纳米科学中心 | 一种基于金纳米簇联合NGF siRNA治疗胰腺癌的方法 |
| EP3458034A4 (en) * | 2016-05-18 | 2020-01-01 | ModernaTX, Inc. | POLYNUCLEOTIDES ENCODING RELAXIN |
| CN106280533B (zh) * | 2016-08-17 | 2018-03-09 | 赣南师范大学 | 一种近红外荧光染料及其合成方法和用于寄生虫荧光标记 |
| EP3292861A1 (en) * | 2016-09-13 | 2018-03-14 | Centre National De La Recherche Scientifique (Cnrs) | An in vitro method for obtaining a biohybrid vector |
| CA3060442A1 (en) * | 2017-04-19 | 2018-10-25 | Apa- Advanced Technologies Ltd. | Fusogenic liposomes, compositions, kits and use thereof for treating cancer |
| CN107084956B (zh) * | 2017-05-05 | 2021-03-23 | 曲阜师范大学 | 一种基于醇溶剂诱导银纳米簇荧光增强的尿液中碘离子检测方法 |
| US11576872B2 (en) * | 2017-05-08 | 2023-02-14 | Flagship Pioneering Innovations V, Inc. | Compositions for facilitating membrane fusion and uses thereof |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| KR20200044806A (ko) | 2017-07-28 | 2020-04-29 | 내셔널 유니버시티 오브 싱가포르 | 변형된 유령 세포를 포함하는 생물분자 복합체 |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| EP3681999A4 (en) * | 2017-09-11 | 2021-06-09 | The Regents of the University of California | CAS9 ANTIBODY MEDIA ADMINISTRATION TO MAMMAL CELLS |
| WO2019066434A1 (ko) * | 2017-09-30 | 2019-04-04 | 주식회사 엑소코바이오 | 사포게닌과 엑소좀을 유효성분으로 포함하는 조성물 |
| KR102008665B1 (ko) * | 2017-09-30 | 2019-08-08 | 주식회사 엑소코바이오 | 사포게닌과 엑소좀을 유효성분으로 포함하는 조성물 |
| EP3710065B1 (en) * | 2017-11-13 | 2024-08-21 | Politecnico Di Torino | Biomimetic non-immunogenic nanoassembly for the antitumor therapy |
| WO2019104242A1 (en) | 2017-11-22 | 2019-05-31 | University Of Louisville Research Foundation, Inc. | Edible plant-derived nanoparticles for regulation of gut microbiota |
| CN108287134B (zh) * | 2017-12-28 | 2020-11-24 | 南京邮电大学 | 单颗粒生物探针及其等离子体生物存储器的构建方法 |
| SG11202007606QA (en) * | 2018-02-17 | 2020-09-29 | Flagship Pioneering Innovations V Inc | Compositions and methods for membrane protein delivery |
| US12241888B2 (en) | 2018-03-14 | 2025-03-04 | Children's Medical Center Corporation | Platform for assessment of the transcytosis of extracellular vesicles across endothelial barriers and uses thereof |
| WO2019195819A1 (en) * | 2018-04-06 | 2019-10-10 | North Carolina State University | Cell assembly-mediated delivery of checkpoint inhibitors for cancer immunotherapy |
| CA3096448A1 (en) | 2018-04-09 | 2019-10-17 | Orgenesis Inc. | Bioxomes particles, redoxomes, method and composition |
| US20210236612A1 (en) * | 2018-04-26 | 2021-08-05 | University Of Louisville Research Foundation, Inc. | Edible plant exosome-like nanovectors for vaccination |
| CA3003032A1 (en) * | 2018-04-27 | 2019-10-27 | Nanostics Inc. | Methods of diagnosing disease using microflow cytometry |
| CN110437628B (zh) * | 2018-05-04 | 2021-05-04 | 中国石油化工股份有限公司 | 一种改性剂母液和道路沥青及其合成方法 |
| US20210228627A1 (en) * | 2018-05-15 | 2021-07-29 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| WO2020002540A1 (en) * | 2018-06-28 | 2020-01-02 | Astrazeneca Ab | Exosome extracellular vesicles and methods of use |
| CA3105953A1 (en) | 2018-07-09 | 2020-01-16 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| KR20210093232A (ko) | 2018-10-09 | 2021-07-27 | 더 유니버시티 오브 브리티시 콜롬비아 | 유기용매와 세제가 없는 형질감염 적격 소포를 포함하는 조성물과 시스템 및 관련 방법 |
| EP3870152A4 (en) * | 2018-10-24 | 2022-10-19 | APA- Advanced Technologies Ltd. | FUSOGENIC LIPOSOMES FOR SELECTIVE IMAGING OF TUMOR CELLS |
| KR20210131991A (ko) | 2018-11-14 | 2021-11-03 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 구획-특이적 카고 전달을 위한 조성물 및 방법 |
| CA3120282A1 (en) * | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
| CN109620969B (zh) * | 2019-01-30 | 2021-02-05 | 广东药科大学 | 一种针对耐药肿瘤细胞的靶向抗肿瘤药物体系及其构建方法 |
| WO2021010586A1 (ko) * | 2019-07-15 | 2021-01-21 | (주)심플스틱 | 항노화를 위한 피부 리프팅용 화장료 조성물 및 이를 이용한 피부미용 방법 |
| EP4013740A4 (en) * | 2019-08-12 | 2023-09-20 | Integrated Nanotherapeutics Inc. | LIPIDS FOR THE ADMINISTRATION OF A LOADED MATERIAL, THEIR FORMULATIONS AND THEIR MANUFACTURING METHOD |
| JP7765681B2 (ja) * | 2019-08-16 | 2025-11-07 | ザ チルドレンズ メディカル センター コーポレーション | エクソソーム模倣物のラージスケール生成およびそれらの使用 |
| CN112415081A (zh) * | 2019-08-23 | 2021-02-26 | 四川大学 | 一种基于稳定同位素检测的无标记CRISPR-Cas9分析方法 |
| KR102297995B1 (ko) * | 2019-10-24 | 2021-09-02 | 포항공과대학교 산학협력단 | 개방 동공을 갖는 산화철 나노큐브, 이의 제조방법 및 이의 용도 |
| CN111007170B (zh) * | 2019-12-13 | 2021-06-29 | 中国农业科学院农产品加工研究所 | 骨肽干预治疗骨质疏松中的生物标志物、筛选方法及用途 |
| EP3858332A1 (en) * | 2020-01-31 | 2021-08-04 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Bottom-up assembly of synthetic extracellular vesicles |
| JP2023513043A (ja) * | 2020-01-31 | 2023-03-30 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子を調製する方法 |
| WO2021173840A1 (en) * | 2020-02-25 | 2021-09-02 | Translate Bio, Inc. | Improved processes of preparing mrna-loaded lipid nanoparticles |
| WO2021186079A1 (en) * | 2020-03-20 | 2021-09-23 | Heidelberg University | Colloidal carrier systems for transfer of agents to a desired site of action |
| WO2022023284A1 (en) | 2020-07-27 | 2022-02-03 | Anjarium Biosciences Ag | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
| CN112094809A (zh) * | 2020-10-19 | 2020-12-18 | 军事科学院军事医学研究院环境医学与作业医学研究所 | 一种从血清或血浆中提取外泌体的方法 |
| US11535869B2 (en) | 2021-04-08 | 2022-12-27 | Sana Biotechnology, Inc. | CD8-specific antibody constructs and compositions thereof |
| US20240226321A1 (en) | 2021-04-14 | 2024-07-11 | Anjarium Biosciences Ag | Peptides, nanovesicles, and uses thereof for drug delivery |
| CA3214659A1 (en) | 2021-04-14 | 2022-10-20 | Joel DE BEER | Fc-derived polypeptides |
| WO2022255851A1 (ko) * | 2021-06-04 | 2022-12-08 | 기초과학연구원 | 나노소포체 반응기 및 이의 제조방법 |
| JP2024528697A (ja) | 2021-07-20 | 2024-07-30 | エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ | 微細藻類由来の細胞外小胞、その調製および使用 |
| WO2023027082A1 (ja) * | 2021-08-23 | 2023-03-02 | 積水化学工業株式会社 | ペプチド結合ハイブリッドリポソームエクソソーム、ペプチド結合エクソソーム、これらを含む組成物及びその形成方法 |
| WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
| WO2023244084A1 (ko) * | 2022-06-17 | 2023-12-21 | 주식회사 엠디뮨 | 양이온성 지질 및 핵산분자를 포함하는 세포유래 베지클 및 이의 제조방법 |
| WO2024088808A1 (en) | 2022-10-24 | 2024-05-02 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof |
| WO2024170778A1 (en) | 2023-02-17 | 2024-08-22 | Anjarium Biosciences Ag | Methods of making dna molecules and compositions and uses thereof |
| US11944604B1 (en) | 2023-03-10 | 2024-04-02 | King Saud University | Nanoformulation of spriooxindole and methods for treating hepatocellular carcinoma |
| WO2024249782A2 (en) * | 2023-06-02 | 2024-12-05 | The Methodist Hospital | Biomimetic proteolipid nanovesicles for delivery of nucleic acids |
| WO2025008499A1 (en) | 2023-07-06 | 2025-01-09 | Anjarium Biosciences Ag | Methods and compositions for purifying particles and macromolecules |
| KR20250018222A (ko) * | 2023-07-26 | 2025-02-05 | 차의과학대학교 산학협력단 | 미토콘드리아가 캡슐화된 세포막 융합유도 리포좀을 포함하는 골관절염 치료를 위한 약학 조성물 |
| WO2025100747A1 (ko) * | 2023-11-09 | 2025-05-15 | 주식회사 엑토좀 | 줄기세포 유래 엑토-리포좀 융합 나노입자 및 그의 용도 |
| WO2025137252A1 (en) * | 2023-12-20 | 2025-06-26 | Cz Biohub Sf, Llc | High throughput method for screening lipid nanoparticle efficacy and cytotoxicity |
| WO2025176843A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof |
| KR20250150723A (ko) * | 2024-04-11 | 2025-10-21 | 주식회사 하이셀텍 | 하이브리드 엑소좀 및 이의 용도 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552155A (en) * | 1992-12-04 | 1996-09-03 | The Liposome Company, Inc. | Fusogenic lipsomes and methods for making and using same |
| US7901708B2 (en) * | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| AU2008207735B2 (en) * | 2007-01-26 | 2013-10-03 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
| US20110224447A1 (en) | 2008-08-18 | 2011-09-15 | Bowman Keith A | Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids |
| WO2010080724A1 (en) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
| ES2927225T3 (es) * | 2009-04-17 | 2022-11-03 | Univ Oxford Innovation Ltd | Composición para entrega de material genético |
| KR100950713B1 (ko) | 2009-07-15 | 2010-03-31 | (주)블루앤 | 음이온 발생기를 구비한 엘이디 램프 |
| US9181295B2 (en) | 2009-08-20 | 2015-11-10 | Sirna Therapeutics, Inc. | Cationic lipids with various head groups for oligonucleotide delivery |
| WO2011043913A2 (en) | 2009-10-08 | 2011-04-14 | Merck Sharp & Dohme Corp. | Novel cationic lipids with short lipid chains for oligonucleotide delivery |
| EP3721943A1 (en) | 2009-12-23 | 2020-10-14 | Novartis AG | Lipids, lipid compositions and methods of using them |
| EP2525781A1 (en) | 2010-01-22 | 2012-11-28 | Schering Corporation | Novel cationic lipids for oligonucleotide delivery |
| US20120315324A1 (en) | 2010-02-05 | 2012-12-13 | University Of Louisville Research Foundation, Inc. | Exosomal compositions and methods for the treatment of disease |
| JP5149921B2 (ja) * | 2010-02-19 | 2013-02-20 | 学校法人君が淵学園 | 癌細胞増殖抑制性ハイブリッド型リポソーム製剤 |
| WO2011127302A2 (en) * | 2010-04-07 | 2011-10-13 | Yue Shen | Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems |
| EP2575895A2 (en) | 2010-05-24 | 2013-04-10 | Merck Sharp & Dohme Corp. | Novel amino alcohol cationic lipids for oligonucleotide delivery |
| US20110293700A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| EP2575767B1 (en) | 2010-06-04 | 2017-01-04 | Sirna Therapeutics, Inc. | Novel low molecular weight cationic lipids for oligonucleotide delivery |
| CN103079592B (zh) * | 2010-07-01 | 2015-10-21 | 浦项工科大学校产学协力团 | 使用来自细胞的微泡治疗和诊断癌症的方法 |
| KR101130137B1 (ko) | 2010-07-02 | 2012-03-28 | 연세대학교 산학협력단 | 발광다이오드 모듈 |
| US20120058154A1 (en) | 2010-08-20 | 2012-03-08 | Selecta Biosciences, Inc. | Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus m2e |
| MX349088B (es) | 2010-09-20 | 2017-07-10 | Merck Sharp & Dohme | Lípidos catiónicos novedosos de bajo peso molecular para la entrega de oligonucleótidos. |
| JP2013545723A (ja) | 2010-09-30 | 2013-12-26 | メルク・シャープ・エンド・ドーム・コーポレイション | オリゴヌクレオチドの送達のための低分子量カチオン性脂質 |
| JP2013545727A (ja) | 2010-10-21 | 2013-12-26 | メルク・シャープ・アンド・ドーム・コーポレーション | オリゴヌクレオチド送達用の新規低分子量カチオン性脂質 |
| DK2635265T3 (en) | 2010-11-05 | 2018-07-16 | Sirna Therapeutics Inc | New low molecular weight cyclic amine-containing cationic lipids for oligonucleotide delivery |
| WO2012099805A2 (en) | 2011-01-19 | 2012-07-26 | Ocean Nanotech, Llc | Nanoparticle based immunological stimulation |
| WO2013048734A1 (en) * | 2011-09-28 | 2013-04-04 | Tufts Medical Center, Inc. | Treatment and prevention of cardiovascular disease with cell derived lipid vesicles, microvesicles and exosomes |
| WO2013086373A1 (en) * | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| JP2013128452A (ja) | 2011-12-21 | 2013-07-04 | Toshiba Corp | 定量分析装置、定量分析方法、脂質膜小胞、及び試薬 |
| CA2891911C (en) | 2012-12-07 | 2023-03-07 | Alnylam Pharmaceuticals, Inc. | Improved nucleic acid lipid particle formulations |
| US20160120818A1 (en) | 2013-02-07 | 2016-05-05 | Glaxosmithline Biological Sa | Pharmaceutical compositions comprising vesicles |
| EP3096741B1 (en) | 2014-01-21 | 2020-09-02 | Anjarium Biosciences AG | Process for the production of hybridosomes |
| WO2022023284A1 (en) | 2020-07-27 | 2022-02-03 | Anjarium Biosciences Ag | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
| CA3214659A1 (en) | 2021-04-14 | 2022-10-20 | Joel DE BEER | Fc-derived polypeptides |
| US20240226321A1 (en) | 2021-04-14 | 2024-07-11 | Anjarium Biosciences Ag | Peptides, nanovesicles, and uses thereof for drug delivery |
| AU2022260111A1 (en) | 2021-04-20 | 2023-11-30 | Anjarium Biosciences Ag | Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof |
| WO2023135273A2 (en) | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
-
2015
- 2015-01-20 EP EP15701846.6A patent/EP3096741B1/en active Active
- 2015-01-20 EA EA201691448A patent/EA037503B1/ru unknown
- 2015-01-20 US US15/112,180 patent/US10561610B2/en active Active
- 2015-01-20 WO PCT/IB2015/050436 patent/WO2015110957A2/en not_active Ceased
- 2015-01-20 CN CN201580005079.XA patent/CN105934240B/zh active Active
- 2015-01-20 KR KR1020237007470A patent/KR102541164B1/ko active Active
- 2015-01-20 CA CA2936514A patent/CA2936514C/en active Active
- 2015-01-20 MX MX2016009529A patent/MX384911B/es unknown
- 2015-01-20 AU AU2015208837A patent/AU2015208837B2/en active Active
- 2015-01-20 KR KR1020227015021A patent/KR102507475B1/ko active Active
- 2015-01-20 DK DK15701846.6T patent/DK3096741T3/da active
- 2015-01-20 KR KR1020167020767A patent/KR102396026B1/ko active Active
- 2015-01-20 ES ES15701846T patent/ES2821758T3/es active Active
- 2015-01-20 JP JP2016546998A patent/JP6598786B2/ja active Active
- 2015-01-20 EP EP20190918.1A patent/EP3791863B1/en active Active
- 2015-01-20 CN CN202110078273.8A patent/CN112870163A/zh active Pending
-
2016
- 2016-07-13 ZA ZA2016/04831A patent/ZA201604831B/en unknown
- 2016-07-21 MX MX2021000174A patent/MX2021000174A/es unknown
-
2019
- 2019-06-19 JP JP2019113819A patent/JP7046872B2/ja active Active
-
2020
- 2020-01-02 US US16/732,567 patent/US11484500B2/en active Active
- 2020-09-07 AU AU2020227129A patent/AU2020227129B2/en active Active
-
2022
- 2022-03-22 JP JP2022045805A patent/JP2022101548A/ja active Pending
- 2022-08-19 AU AU2022218603A patent/AU2022218603B2/en active Active
- 2022-09-12 US US17/942,617 patent/US11944706B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017502997A5 (enExample) | ||
| JP2019218349A5 (enExample) | ||
| CN102119217B (zh) | 用于核酸递送的新型制剂 | |
| US10653780B2 (en) | Amino lipids and methods for the delivery of nucleic acids | |
| JP5977394B2 (ja) | 脂質に封入された干渉ｒｎａ | |
| US20110117125A1 (en) | Compositions and methods for the delivery of nucleic acids | |
| US20120264810A1 (en) | Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles | |
| JP5464556B2 (ja) | 新規の正イオン性脂質、それの製造方法、およびそれを含む伝達体 | |
| JP6192061B2 (ja) | 中性脂質を含む両性リポソーム | |
| CN105916839B (zh) | 阳离子性脂质 | |
| JP2011507534A5 (enExample) | ||
| US20180016583A1 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| US20180245077A1 (en) | Compositions and methods for treating hypertriglyceridemia | |
| CA3123595A1 (en) | Nanoparticle compositions for efficient nucleic acid delivery and methods of making and using the same | |
| JP2015525209A5 (enExample) | ||
| Sen et al. | Design, syntheses, and transfection biology of novel non-cholesterol-based guanidinylated cationic lipids | |
| US20110313017A1 (en) | Snalp formulations containing polyoxazoline-dialkyloxypropyl conjugates | |
| NL2033672B1 (en) | Compounds and compositions for delivery of agents to cells | |
| US20140178462A1 (en) | Amphoteric liposomes comprising neutral lipids | |
| JP7043411B2 (ja) | カチオン性脂質としての化合物 | |
| WO2024057237A1 (en) | Lipid nanoparticles | |
| HK1160459B (en) | Improved amino lipids and methods for the delivery of nucleic acids |